A $45 million jury verdict is bad enough. Getting nearly a half-billion dollars knocked off your market cap—and almost $200 million added to your competitor’s—might be even worse.

That was the market fallout Tuesday for molecular diagnostic company Natera Inc. after losing a five-day jury trial to competitor CareDx Inc. over false advertising and unfair competition.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]